What it is
Mazdutide is a dual agonist: a single engineered peptide that activates two receptors at once, GLP-1 and glucagon. It is modelled on oxyntomodulin, a gut hormone the body already makes that acts at both.
The two activities pull in interestingly different directions. GLP-1 activation suppresses appetite and improves blood-sugar control. Glucagon activation increases energy expenditure — but glucagon on its own also raises blood sugar, which is the tension the molecule is designed around.
It appears in the trial record under two names, IBI362 and LY3305677, because Innovent Biologics licensed it from Eli Lilly.
What is unusual about it
Almost every compound in this library has the same shape of evidence problem: one company studies it, and no one else does. The amylin analogue cagrilintide has 43 trial registrations and every single one belongs to Novo Nordisk. The triple-agonist entry records 33, of which 32 belong to Eli Lilly. When that is the pattern, everything known about a compound passes through one interested party.
Mazdutide does not have that pattern. Its 41 registrations, checked on 2026-09-09, come from fifteen different lead sponsors:
| Sponsor | Registrations |
|---|---|
| Innovent Biologics | 19 |
| Eli Lilly and Company | 7 |
| Thirteen Chinese hospitals and universities | 13 |
| Two named individual investigators | 2 |
The hospitals in that third row — Tongji, West China, Shanghai Zhongshan, Beijing Friendship, Shandong Provincial, the Nanjing Drum Tower hospital, Tianjin Medical University and others — filed their studies themselves. That is what an independent literature looks like at the point it starts to exist, and it is worth naming because it is rare here.
None of this says mazdutide works better than anything else. It says the evidence has more than one author.
Where it stands
The phase 3 programme is substantial: 12 registrations, 5,118 participants planned or enrolled between them. Study sites are split almost evenly between the United States (107) and China (93), with a handful in Argentina, the United Kingdom and Germany.
What does not exist is a US approval. A DailyMed search for mazdutide on 2026-09-09 returned no records at all — no label, no approved indication, no dose, no contraindications, no warnings. For a compound being sold online right now, that absence is the whole story, because a label is not a formality: it is the document in which a regulator states who a drug is for and what must be watched.
PubMed indexed 50 mazdutide records on the same date. A large registry and a small literature is the normal shape of a drug still inside its development programme — the results exist mostly as trial records, not yet as published papers.
How it sits beside the others
This library covers the whole family, and the differences between them are receptor arithmetic more than anything else:
- Semaglutide — GLP-1 alone, and the only one of the group with a mature approved-label history.
- The approved dual agonist — GLP-1 and GIP.
- Mazdutide — GLP-1 and glucagon.
- The triple agonist in this group — GLP-1, GIP and glucagon.
- Cagrilintide — a different hormone family altogether (amylin), developed as a partner rather than a replacement.
- Orforglipron — the same GLP-1 receptor, reached by a small molecule rather than a peptide.
Ranking them is not something this library does, and in this case it is not something the evidence supports either: the head-to-head trials exist, but most of them have not reported.